Jun 17, 2020
Respira Technologies, Inc. announces plan to pursue FDA authorization for the RespiRxTM drug delivery platform as the first "vapor style" Nicotine Replacement Therapy targeting the 50% of smokers who want to quit
Jun 11, 2020
Global Pandemic of Smoking-related Disease to Kill Seven Million More in 2020: Viable Solutions Blocked by Moral Panics and Big Philanthropy
May 14, 2020
Achieve Reports Financial Results for First Quarter 2020 and Provides Update on Cytisinicline Development Program
May 11, 2020
COVID-19 Social Distancing and Stay-at-Home Policies Lead to Increased Dependence on Tobacco as Stress Coping Tool
Apr 30, 2020
Achieve Life Sciences Announces Private Placement of $1.9 Million
Mar 16, 2020
The Global Smoking Cessation and Nicotine De-addiction Market is expected to grow by USD 16.6 bn during 2020-2024, progressing at a CAGR of 13% during the forecast period
Mar 13, 2020
Achieve Reports Financial Results for Fourth Quarter and Year-End 2019 and Provides Update on Cytisinicline Development Program
Mar 12, 2020
Achieve Life Sciences Announces Presentation of Additional Cytisinicline Analyses at the Society for Research on Nicotine & Tobacco (SRNT) Annual Meeting
Feb 24, 2020
The Global Smoking Cessation and Nicotine De-Addiction Market is expected to grow by USD 16.6 bn during 2020-2024, progressing at a CAGR of 13% during the forecast period
Jan 13, 2020
Achieve Life Sciences, University of Bristol, and Oracle Corporation Announce Study Results Demonstrating Potential for Accelerated Speed of Drug Discovery
Dec 17, 2019
FDA permits sale of two new reduced nicotine cigarettes through premarket tobacco product application pathway
Dec 09, 2019
Achieve Life Sciences Announces Completion of Meeting with the U.S. Food & Drug Administration (FDA) on Cytisinicline Smoking Cessation Phase 3 Clinical Development Program
Nov 12, 2019
IntelliQuit's Cloud Based Nicotine Bio-Monitoring Measures Nicotine Consumption in Vapers Aiding Treatment
Sep 13, 2019
Achieve Life Sciences Announces Final Phase 2b ORCA-1 Trial Data Presented at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference
Sep 09, 2019
FDA warns JUUL Labs for marketing unauthorized modified risk tobacco products, including in outreach to youth
Sep 05, 2019
Achieve Life Sciences to Host Investor Day on September 20th Including Roundtable Discussion with Smoking Cessation Medical Experts and Final Data from the Phase 2b ORCA-1 Trial
Sep 04, 2019
Innovative Drug-Delivery Systems Benefit Patients and Businesses
Sep 04, 2019
Achieve Life Sciences Announces Presentations at Upcoming Investor Conferences
Jul 23, 2019
Achieve Life Sciences Extends Collaboration with the National Institutes of Health to Advance the Development of Cytisinicline for Smoking Cessation
Jul 18, 2019
World's 1st Cloud Based Nicotine Monitoring for All Tobacco Users and Their Doctors